Development and validation of a genomic mutation signature to predict response to PD-1 inhibitors in non-squamous NSCLC: a multicohort study
Background Genetic variations of some driver genes in non-small cell lung cancer (NSCLC) had shown potential impact on immune microenvironment and associated with response or resistance to programmed cell death protein 1 (PD-1) blockade immunotherapy. We therefore undertook an exploratory analysis t...
Saved in:
| Main Authors: | Jian Wang, Yi-Long Wu, Xue Bai, De-Hua Wu, Si-Cong Ma, Xin-Ran Tang, Shuai Kang, Qiang John Fu, Chuan-Hui Cao, He-San Luo, Yu-Han Chen, Hong-Bo Zhu, Hong-Hong Yan, Zhong-Yi Dong |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2020-05-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/8/1/e000381.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Correction: Development and validation of a genomic mutation signature to predict response to PD-1 inhibitors in non-squamous NSCLC: a multicohort study
Published: (2020-10-01) -
Mutation-guided chemotherapy-free strategy in first-line immunotherapy for low PD-L1-expressing non-squamous NSCLC
by: Hui Li, et al.
Published: (2024-11-01) -
Association of pre-existing conditions with major driver mutations and PD-L1 expression in NSCLC
by: Xin Zheng, et al.
Published: (2024-12-01) -
Plasma IL-6 changes correlate to PD-1 inhibitor responses in NSCLC
by: Mariano Severgnini, et al.
Published: (2020-10-01) -
Elucidating the potential of EGFR mutated NSCLC and identifying its multitargeted inhibitors
by: Anakha D. Rajeeve, et al.
Published: (2025-01-01)